Profile ready
Bio · photo · LinkedIn
Profile complete: bio, photo and LinkedIn URL added.
Active advisor
Applied in last 6 months
Applied to at least one opportunity in the past 6 months.
About
%22I bring 25+ years of global life sciences experience at the intersection of commercial strategy and operational execution — spanning oncology, immunology, and cell & gene therapy. I%27ve built commercial organizations from the ground up, led complex multi-market launches across Europe, managed P&Ls of €100M+, and steered organizations through the full asset lifecycle from late-stage development to portfolio divestment. My rare combination of C-suite commercial leadership and a deep finance foundation means I don%27t just challenge strategy — I challenge the assumptions behind it.%22
Why I add value on a board
- Commercial & Finance Fluency — Career spanning EMEA Finance Director to VP Commercial makes me uniquely effective at interrogating business cases, forecasts, and capital allocation.
- Advanced Therapy Expertise — Hands-on experience building ATMP commercial infrastructure in Europe
- Launch Readiness Oversight — Pattern recognition across multiple blockbuster launches enables early identification of execution risk before it becomes shareholder risk.
- Alliance & Partnership Governance — Seasoned in co-commercialization complexity; understands where partnerships create value and where they create risk.
- European Market Depth — Genuine EU5 & EMEA operational experience, invaluable for US or Asian biotechs building or stress-testing European strategy.
Where I%27m most impactful:
- Pre-commercial Biotech (EU): Launch readiness, go-to-market design, market access strategy
- US/APAC Biotech entering Europe: EMEA commercial build-out, reimbursement navigation
- Cell & Gene Therapy Companies: ATMP commercial infrastructure, supply & access model design
- Specialty Pharma with BD Activity: Commercial due diligence, asset prioritization
- Co-commercialization Ventures: Alliance governance, execution alignment
PE/VC-backed Life Sciences - Value creation planning, commercial transformation
- Start ups in lifesciences
Why I add value on a board
- Commercial & Finance Fluency — Career spanning EMEA Finance Director to VP Commercial makes me uniquely effective at interrogating business cases, forecasts, and capital allocation.
- Advanced Therapy Expertise — Hands-on experience building ATMP commercial infrastructure in Europe
- Launch Readiness Oversight — Pattern recognition across multiple blockbuster launches enables early identification of execution risk before it becomes shareholder risk.
- Alliance & Partnership Governance — Seasoned in co-commercialization complexity; understands where partnerships create value and where they create risk.
- European Market Depth — Genuine EU5 & EMEA operational experience, invaluable for US or Asian biotechs building or stress-testing European strategy.
Where I%27m most impactful:
- Pre-commercial Biotech (EU): Launch readiness, go-to-market design, market access strategy
- US/APAC Biotech entering Europe: EMEA commercial build-out, reimbursement navigation
- Cell & Gene Therapy Companies: ATMP commercial infrastructure, supply & access model design
- Specialty Pharma with BD Activity: Commercial due diligence, asset prioritization
- Co-commercialization Ventures: Alliance governance, execution alignment
PE/VC-backed Life Sciences - Value creation planning, commercial transformation
- Start ups in lifesciences
Advisory experience
Geert Van Gils is an advisor and board member based in Belgium. They have advisor or board member experience with UBS - Ayano. They are open to advisory board and board director opportunities and are available for introductions through Boardio.
Boardio matches companies with experienced advisors and board members across 120 countries — this is one of 12k+ profiles in the network.
Looking for advisors?
Browse now
Interested in becoming an advisor?
See opportunities
